LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Agios Pharmaceuticals Inc

Open

SectorHealthcare

34.11 3.58

Overview

Share price change

24h

Current

Min

33

Max

34.25

Key metrics

By Trading Economics

Income

7.2M

-89M

Sales

-2M

8.7M

P/E

Sector Avg

2.889

50.291

EPS

-1.55

Profit margin

-1,023.252

Employees

486

EBITDA

17M

-107M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+69.99% upside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

94M

2B

Previous open

30.53

Previous close

34.11

News Sentiment

By Acuity

100%

0%

366 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Agios Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 wrz 2024, 14:20 UTC

Acquisitions, Mergers, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Peer Comparison

Price change

Agios Pharmaceuticals Inc Forecast

Price Target

By TipRanks

69.99% upside

12 Months Forecast

Average 57.2 USD  69.99%

High 71 USD

Low 50 USD

Based on 8 Wall Street analysts offering 12 month price targets forAgios Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

6

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

28.04 / 30.06Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

366 / 380 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.